Justin B. Klee insider trades: Amylyx Pharmaceuticals (AMLX) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Justin reports to the SEC
Open-market buys and sales
15 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Sep 10, 2026 | AMLX | ↓ Sell | 30,464 | $32.18 | $980K | Direct | Sep 14, 2026 (4d) |
| Mar 2, 2026 | AMLX | ↓ Sell | 29,282 | $14.47 | $424K | Direct | Mar 4, 2026 (2d) |
| Feb 2, 2026 | AMLX | ↓ Sell | 15,500 | $14.69 | $228K | Direct | Feb 4, 2026 (2d) |
| Jan 16, 2026 | AMLX | ↓ Sell | 138,188 | $13.59 | $1.9M | Direct | Jan 20, 2026 (4d) |
| Jan 6, 2026 | AMLX | ↓ Sell | 7,715 | $11.09 | $86K | Direct | Jan 8, 2026 (2d) |
| Sep 30, 2025 | AMLX | ↓ Sell | 29,975 | $14.38 | $431K | Direct | Oct 2, 2025 (2d) |
| Mar 31, 2025 | AMLX | ↓ Sell | 21,490 | $3.46 | $74K | Direct | Apr 2, 2025 (2d) |
| Mar 3, 2025 | AMLX | ↓ Sell | 4,595 | $3.15 | $14K | Direct | Mar 5, 2025 (2d) |
| Feb 3, 2025 | AMLX | ↓ Sell | 11,855 | $3.47 | $41K | Direct | Feb 5, 2025 (2d) |
| Jan 6, 2025 | AMLX | ↓ Sell | 7,471 | $4.04 | $30K | Direct | Jan 8, 2025 (2d) |
| Sep 30, 2024 | AMLX | ↓ Sell | 18,589 | $3.20 | $59K | Direct | Oct 2, 2024 (2d) |
| Mar 5, 2024 | AMLX | ↓ Sell | 4,135 | $18.73 | $77K | Direct | Mar 7, 2024 (2d) |
| Jan 9, 2024 | AMLX | ↓ Sell | 5,841 | $16.33 | $95K | Direct | Jan 11, 2024 (2d) |
| Mar 16, 2023 | AMLX | ↓ Sell | 100,000 | $31.86 | $3.2M | Direct | Mar 20, 2023 (4d) |
| Jan 6, 2023 | AMLX | ↓ Sell | 5,968 | $36.30 | $217K | Direct | Jan 10, 2023 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other AMLX insiders
Open-market trades in the last 12 months
About Justin B. Klee's insider trades
Justin B. Klee is Co-Chief Executive Officer at Amylyx Pharmaceuticals (AMLX). Since Jan 6, 2023, Justin has reported no open-market purchases and 15 sales worth $7.8M on SEC Form 4. In the last 12 months: 5 sales ($3.6M).
Their filings also include grants and awards (7 filings), option exercises (4 filings), conversions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every AMLX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.